Profile data is unavailable for this security.
About the company
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
- Revenue in USD (TTM)12.34bn
- Net income in USD815.64m
- Incorporated1994
- Employees70.00k
- LocationDaVita Inc2000 16th StDENVER 80202-5158United StatesUSA
- Phone+1 (310) 536-2668
- Fax+1 (302) 636-5454
- Websitehttps://www.davita.com/
Mergers & acquisitions
| Acquired company | DVA:NYQ since announced | Transaction value |
|---|---|---|
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Brazil | 7.17% | 300.00m |
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Chile | 7.17% | -- |
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Colombia | 7.17% | -- |
| Fresenius Medical Care AG & Co KGaA-Dialysis Clinic Network,Ecuador | 7.17% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ensign Group Inc | 3.85bn | 218.38m | 6.80bn | 35.30k | 31.45 | 4.31 | 23.13 | 1.76 | 3.80 | 3.80 | 66.98 | 27.73 | 0.9431 | -- | 8.00 | 109,141.30 | 5.36 | 6.45 | 6.37 | 7.88 | 21.54 | 22.32 | 5.68 | 6.48 | -- | 40.62 | 0.0858 | 6.56 | 23.27 | 16.28 | -6.80 | 28.62 | 4.40 | 5.02 |
| Chemed Corp | 2.29bn | 283.41m | 8.48bn | 15.09k | 30.14 | 7.14 | 24.55 | 3.70 | 18.58 | 18.58 | 150.33 | 78.46 | 1.45 | 138.48 | 13.85 | 152,017.80 | 17.94 | 19.53 | 21.86 | 24.64 | 35.47 | 34.60 | 12.36 | 12.60 | 1.88 | -- | 0.0114 | 8.15 | 6.06 | 4.90 | 9.17 | 5.80 | 1.46 | 6.10 |
| Encompass Health Corp | 4.96bn | 386.50m | 8.64bn | 22.36k | 22.57 | 4.96 | 11.06 | 1.74 | 3.80 | 3.68 | 48.76 | 17.30 | 0.8276 | -- | 8.74 | 221,721.20 | 8.36 | 6.37 | 10.58 | 7.94 | 95.50 | 95.58 | 10.10 | 9.16 | -- | 5.59 | 0.5298 | 30.78 | 10.41 | 2.34 | 41.31 | 4.49 | 16.60 | -10.42 |
| Solventum Corp | 8.20bn | 1.29bn | 10.57bn | 22.01k | 8.18 | 2.75 | 5.73 | 1.29 | 7.48 | 7.48 | 47.54 | 22.30 | -- | -- | -- | 372,699.60 | -- | -- | -- | -- | 57.64 | -- | 15.73 | -- | 1.33 | 43.79 | 0.6832 | -- | 0.8241 | -- | 0.2234 | -- | -- | -- |
| Universal Health Services, Inc. | 14.66bn | 816.29m | 11.94bn | 73.35k | 15.28 | 1.93 | 8.59 | 0.8145 | 11.79 | 11.79 | 211.29 | 93.48 | 1.06 | -- | 6.77 | 199,837.00 | 5.96 | 6.44 | 6.98 | 7.63 | -- | -- | 5.61 | 6.55 | 1.28 | 6.16 | 0.4352 | 6.06 | 6.59 | 5.80 | 6.32 | -1.47 | 1.17 | 14.87 |
| Davita Inc | 12.34bn | 815.64m | 12.16bn | 70.00k | 15.75 | 13.14 | 6.59 | 0.9858 | 8.81 | 8.81 | 133.10 | 10.56 | 0.7224 | 66.04 | 5.30 | 176,257.20 | 6.40 | 5.62 | 8.50 | 7.45 | 32.40 | 30.70 | 8.85 | 8.33 | 1.37 | 5.01 | 0.7759 | -- | 4.57 | 1.26 | 26.44 | 2.33 | -10.47 | -- |
| Tenet Healthcare Corp | 20.90bn | 2.62bn | 12.73bn | 78.14k | 5.04 | 3.69 | 3.02 | 0.6094 | 25.87 | 25.87 | 201.91 | 35.35 | 0.7466 | 9.04 | 6.50 | 267,391.00 | 11.97 | 3.61 | 17.38 | 5.09 | 82.64 | 82.97 | 16.03 | 4.95 | 1.37 | 4.49 | 0.6267 | 0.00 | 7.17 | 2.33 | 49.02 | 41.42 | 4.01 | -- |
| Quest Diagnostics Inc | 9.29bn | 842.00m | 15.92bn | 40.00k | 19.29 | 2.47 | 12.08 | 1.71 | 7.43 | 7.43 | 82.00 | 57.95 | 0.6944 | 33.57 | 7.21 | 232,175.00 | 6.51 | 9.28 | 7.61 | 10.81 | 32.95 | 36.64 | 9.37 | 12.97 | 0.8908 | 8.40 | 0.4184 | 25.07 | -6.38 | 4.20 | -9.77 | 3.40 | 1.27 | 7.43 |
| Laboratory Corporation of Amerc Holdings | 12.30bn | 399.20m | 17.31bn | 67.00k | 44.96 | 2.17 | 17.91 | 1.41 | 4.57 | 4.95 | 142.45 | 94.42 | 0.6698 | 18.59 | 4.68 | 183,588.10 | 2.18 | 6.27 | 2.68 | 7.37 | 27.74 | 32.33 | 3.25 | 9.51 | 0.7564 | 5.95 | 0.3934 | -- | 2.51 | 1.42 | -62.16 | -16.40 | 3.62 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Berkshire Hathaway, Inc. (Investment Management)as of 31 Mar 2024 | 36.10m | 41.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.03m | 6.87% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.20m | 3.65% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.58m | 2.94% |
| Pacer Advisors, Inc.as of 31 Mar 2024 | 1.68m | 1.92% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.27m | 1.45% |
| Invesco Capital Management LLCas of 31 Mar 2024 | 1.19m | 1.36% |
| LSV Asset Managementas of 31 Mar 2024 | 1.12m | 1.27% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.00m | 1.14% |
| Gates Capital Management, Inc.as of 31 Mar 2024 | 762.57k | 0.87% |
